Kanker-actueel Immunotherapy for colon cancer: radio-immunotherapy with CEA antibody shows promising results in phase II trial with 30 cancer patients.

CANCER.

Information on current developments in both regular and alternative or complementary treatments for cancer types and resources at all stages. We have basically all articles and information put in alphabetical order, scroll in left column in alphabetical list.

Experiences of cancer patients with complementary approaches can be found by experience stories and there are also some videos of experiences of cancer patients to see. To click on video button top left . Or visit the website of the SNFK information where movies are shown on complementary approaches to cancer.

Immunotherapy for colon cancer: radio-immunotherapy with CEA antibody shows promising results in phase II trial with 30 cancer patients.

The company Immunomedics reports in an article in the journal Cancer (15 Febr. 2002) that a Phase II trial with 30 metastatic colorectal cancer patients treated with radio-immunotherapy significant differences gave and hopefully vote for the treatment of cancer patients to prevent a recurrence. I have freely translated article below, but please ask your doctor / oncologist if my translation is correct. Incidentally, I understand that the VU Amsterdam and Nijmegen Radbout trials run with a form of self-immunization, but am not sure.

Moreover, it seems that following the Houtsmuller diet supplemented with supplementation and in conjunction with any maintenance chemo (5FU) also prevents colorectal cancer patients relapse develop, but there are no scientific studies done, but only experience stories of patients. Who is interested will contact an orthomolecular doctor. (see page useful addresses) for liver metastases in colorectal cancer has come down from RFA may be an option. See RFA-cancers.

Feb. 28. Immunomedics press release:
This publication reports Phase II study results of 30 cancer patients using the I-131-labeled humanized CEA antibody given. Two groups of patients were studied. Measured in 21 patients with metastatic colorectal cancer, and 9 patients whose metastases were removed by previous treatments (additional group). Both groups received a single dose of the product, including 5 patients with confirmed recurrent half received treatment after 8-16 months after initial treatment. The re-treated patients had either partial or minor response shown after the first treatment and were then given a recurrence. After reviewing his treatment showed two of the four a partial remission (more than 50% reduction in tumor size) and another showed a stabilization due to the second treatment. Of 19 available patients in the first group with measurable metastatic cancer experienced minor 3 (16%) partial remission and eight showed minor responses.

The responses had a duration of 15 months and an average response lasted 9 months. these reactions give all together a response rate of 58%. The researchers report that 7 of 9 (78%) patients in the second, additional treatment group remained free of disease for 36 months, the date this article was written. (1 patient had a relapse after 6 months, another after 30 months). In comparison, only 33% of patients in a comparable historical control group who received standard chemotherapy after post-surgery in the same hospital and in the same period were free of the disease. The only "toxicity" that was seen in cells which had been a patient of the 28 available patients a severe fall of platelet-platelet ('flat fillets ") got. Even after repeated treatment in 5 patients, none of the patients showed an increase in toxicity compared with other patients, the authors say.

"This first analysis of our results shows clearly that radio-immunotherapy with the experimental agents a relatively safe and promising treatment seems to be for cancer with small tumors and has potential as a treatment in one additional setting after a complete removal of metastases," says Prof. Thomas M. Behr, lead author of this article. "Since the tumors of most patients with colorectal cancer show large amounts of CEA, this treatment can be used in many such patients with a common untreatable cancer. This study was conducted at the University of Göttingen.
Cynthia L. Sullivan, President and CEO of Immunomedics observes: "It is remarkable that the group with distant metastatic colorectal cancer who received additional chemotherapy after the majority (67%) developed recurrence within three years, while only 2 of 9 patients had a recurrence after only one injection of CAE antibody. We plan to translate these results in larger, controlled trials in several countries.

This single phase II study, now applied to larger numbers of patients are summarized and based on the results and we will see how to follow up with trials in several hospitals and medical centers. Ms.. Sullivan says, "Based on the results of a single treatment in most patients and a repeat treatment in 5 patients without significant toxicity, we are hopeful and believe that even aeffectiveness can be achieved in patients who undergo a dual therapy with these radioactive CEA antibody.

For further information see: Company Contact: Rebecca Kinner, Investor Relations, (973) 605-8200, extension 263. Visit the company's Web site at http://www.Immunomedics.com.

- PRESS RELEASE: Immunomedics Phase II Results Published -

Encouraging Phase II Trial Results in the Therapy of Advanced Colorectal
Cancer Patients Published
MORRIS PLAINS, NJ, February 28 / PRNewswire-FirstCall / - Immunomedics, Inc..
(Nasdaq: IMMU) Reported today the publication of an article on clinical trial
ITS results with radiolabeled, humanized antibody against carcinoembryonic
antigen (CEA) in the February 15, 2002, Supplement issue to the journal Cancer,
a publication of the American Cancer Society.
This publication Reported Phase II results of 30 colorectal cancer patients
Given the I-131-labeled humanized CEA antibody. Two sets of Patients Were
studied, 21 with meta-static colorectal cancer Measurable, who had 9 and Their
Completely resected metastases prior to therapy (adjuvant group). Both groups
Received a single dose of the product, whereas 5 patients with tumor Documented
Recurrence Received a second treatment 8-16 months after the first therapy. The
patiënten had retreated Shown Either partial or minor responses to the first
treatment and then relapsed. After retreat apartment, 2 or 4 showed a partial
remission (more Than 50% Decrease in tumor size), and another showed
Stabilization of disease as a conséquence of the second treatment.
Of 19 assessable patients in the first group with measurable, small-volume,
meta-static cancer, 3 (16 percent) Experienced a partial remission and eight showed
minor responses. The responses had a duration of up to 15 months, with an
average duration of response or 9 months. These results correspond to an overall
response rate of 58 percent.
Reported That the authors of the September 7 (78%) patients in the second, adjuvant
treatment group remained free of disease for up to 36 months, When The data Were
Summarized for this article (one patient relapsed after 6 months and another
after 30 months). In comparison, only 33 percent of patients in a historical
control group, who Received standard chemotherapy post-surgery at the Same
hospital and over the sametime period, Were free of disease.
The only toxicity was observed to blood cells, where clause 1 or 28 assessable
patiënten Developed a transiently severe drop in flat fillets. Even after repeated
treatment in 5 patients, none of the Patients showed an Increased toxicity,
According To the authors.

"This initial analysis of our results suggests Clearly That radio immunotherapy
with this experimental agent Appears to Be a Relatively safe and promising form
or therapy for small-volume colorectal cancer, and HAS as a potential treatment
for colorectal cancer in an adjuvant setting or following complete resection
metastases, Stated Professor Thomas M. Behr, lead author of the article. "Since
Patients with tumors or must the colorectal cancer express high Amount of CEA,
Should this therapy be of use to many Such patiënten with this gene rally
Unresponsive cancer, "he said Further. The study was Performed at the University
of Gottingen, Germany.
Cynthia L. Sullivan, President and CEO of Immunomedics, remarked: "It Should
That be appreciated in the group with resected colorectal cancer metastases
receiving post-operative adjuvant chemotherapy, the Majority (67 percent)
relapsed Within 3 years, whereas only 2 of 9 showed cancer Recurrence after a
single injection of this CEA antibody. We plan to confirm early results in synthesis
larger, controlled trials. "

"This single-site Phase II study, now Encompassing a larger number of
patients, being Summarized and, based on the results, we want determining how
to proceed with multicenter trials, "she added.
Ms. Further Sullivan Stated: "Based on the results of a single treatment at
wine and a repeated therapy in 5 patients without limiting toxicities, we are
encouraged to Believe That May Be Possible even better efficacy in patiënten
receiving two courses of this radioactive CEA antibody, but this needs to be
studied in the next trial, "she Clarified." Since the antibody is humanized,
Galanthus being about 90% human, we do not Anticipate Any problems with an immune
response to the antibody therapeutic, "Ms.. Sullivancommented.